The study will evaluate the combination of NEO-PV-01 with nivolumab (anti-PD-1 therapy) in metastatic or advanced melanoma patients
Neon Therapeutics Inc., an immuno-oncology company which develops neoantigen-based treatments has reportedly presented updated data that describes pathologic and immune markers related with durable clinical advantages in patients enrolled in NT-001.
NT-001, for the record, is an ongoing Phase 1b clinical trial for evaluating the combination of NEO-PV-01 with nivolumab (anti-PD-1 therapy) in metastatic or advanced melanoma patients. Apparently, in an oral presentation these data were highlighted at the Annual Meeting of American Association for Cancer Research (AACR) in Atlanta.
According to Neon Therapeutics Inc, NEO-PV-01 is a personal neoantigen vaccine which is manufactured and custom-designed on the basis of neoantigens identified as being therapeutically relevant for an individual patient by the proprietary bioinformatics engine of Neon, RECON.
Neon said the presented data consisted of 23 metastatic melanoma patients who had received not less than one dose of NEO-PV-01 and who either progressed by 36 weeks after the commencement of anti-PD-1 therapy or had remained progression-free. In addition, those patients who did not progress by 36 weeks were named as having DCB, durable clinical benefit.
Seemingly, as per data, it indicates RECON-based prediction of neoantigen quality corresponds with DCB and works as clinical validation for the ability of RECON to recognize therapeutically relevant neoantigens.
The new analysis of the company has displayed two post-vaccine markers, tumor pathology and epitope spread which certainly relate to durable clinical benefit. Out of patients tested, the company observed spread of epitope in all the patients with DCB. Moreover, the patients with DCB displayed marked depletion in tumor content only after the vaccination.
The company officials are encouraged by these results and look forward to evaluating patient’s outcomes including progression-free survival and clinical responses. The analysis which is presented at AACR highlights new data on DCB in the melanoma cohort and its relationships with multiple molecular and histological markers, besides confirming mechanism action of NEO-PV-01.